Health

Next-generation and personalised therapies are redefining treatment strategies by aligning interventions with individual biological characteristics and disease mechanisms. Biomarker-guided approaches, precision medicine frameworks and stratified clinical models enable more targeted and effective care. Progressing from discovery to clinical implementation requires integrated translational structures, regulatory alignment and coordinated collaboration between research, clinical and innovation actors.

By structuring cross-sector consortia and aligning scientific, regulatory and innovation planning, we support the advancement of therapeutic concepts toward scalable, safe and impactful real-world applications.

Advanced Therapy Medicinal Products (ATMPs), which include cell and gene therapies, biomaterials and regenerative technologies, are advancing the field of curative medicine. Developing these products requires more than scientific excellence; it demands coordinated governance, effective navigation of the regulatory landscape, and sustainable innovation planning. The complex manufacturing processes, evolving regulatory requirements and substantial investment required make structured collaboration across academia, clinics, industry, SMEs and policymakers essential.

We design and manage collaborative frameworks that guide advanced therapies through the entire translational process, from early research to the clinical validation and uptake of innovations. Through integrated consortium management, independent innovation support, and knowledge valorisation expertise, we contribute to strengthening Europe’s ATMP landscape and enabling lasting societal impact.

Infectious threats are constantly evolving in response to global mobility, environmental change and demographic shifts. Effective preparedness therefore requires the integration of biomedical innovation with surveillance systems, data infrastructures and coordinated public health strategies. Our projects focus on vaccine platforms, mRNA-based antivirals, broad-spectrum therapeutics, diagnostics and preparedness frameworks. A sustainable response capacity depends on interoperability, modelling tools and cross-border cooperation. This also reinforces broader preparedness and resilience capacities across European health systems.

By coordinating large, interdisciplinary consortia, we help translate scientific advances into structured and adaptive health security architectures, thereby reinforcing Europe’s capacity to prevent, detect and respond to emerging threats.

Improving health outcomes requires systemic innovation that goes beyond therapeutic development. Central to achieving equitable and sustainable impact are prevention strategies, health systems research and regulatory advancement. Aligning scientific evidence with governance structures and policy frameworks ensures that innovation is implemented responsibly and on a larger scale. Regulatory science, policy modelling and stakeholder engagement all play a critical role in this process.

By facilitating structured collaboration between researchers, regulators, policymakers and societal stakeholders, we can enable health innovations to progress beyond the pilot stage and become embedded within European health systems in a sustainable way.